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Abstract 
Background: Patients with Pseudomonas aeruginosa infections from blood or sterile sites were evaluated to deter-
mine risk factors associated with carbapenem resistance (CRPA) compared to carbapenem sensitivity (CSPA) as well as 
prior carbapenem use and the development of resistance.
Findings: Retrospective chart review of 80 patients hospitalized with a documented P. aeruginosa infection during 
2010–2011. Stored isolates were retested with both Kirby–Bauer disk diffusion and E-tests. Clinical characteristic of 
patients in the CRPA (N = 21) and the CSPA (N = 59) groups were similar. Hospital acquired (HA) infections were more 
common in the CRPA group compared to the CSPA group (71 vs 44 %, p = 0.04) and CRPA patients were more likely 
to have a Foley catheter at the time of infection (71 vs 37 %, p = 0.01). There was more carbapenem use in the CRPA 
group prior to onset of infection (59 vs 22 %, OR 5.1, 95 % CI 1.3–20.8, p = 0.01). Length of stay was significantly longer 
in the CRPA group (mean 44 days) compared to the CSPA group (mean 23 days), p = 0.02. Mortality between the two 
groups was similar and there were no differences between groups for death attributable to Pseudomonas.
Conclusions: Patients with CRPA were more likely to have HA infections and to have a multidrug resistant profile. 
Other identifiable risks included a Foley catheter in place at the time of infection and exposure to a carbapenem prior 
to infection. Prompt removal of devices and judicious use of antibiotics may be interventions that can impact the 
development of this kind of infections.
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Background
Risk factors for developing a Pseudomonas aeruginosa 
blood stream infection include the presence of a urinary 
device, antimicrobial use within 30  days and the pres-
ence of a central venous catheter (CVC) (Schechner et al. 
2009). Identifying risk factors for multi-drug resistant 
P. aeruginosa is especially of interest due to the limited 
number of agents that have good activity against this 
organism.
The University of Colorado Hospital (UCH) is a tertiary 
care academic medical center. Antibiogram data has been 
used to make adjustments to the hospital’s formulary. Fluo-
roquinolones became restricted house-wide in 2004 due to 
increased resistance. Ertapenem was added to the formu-
lary in November 2004. Imipenem was removed from the 
formulary in 2007 and meropenem in 2010. Doripenem 
was introduced to the UCH formulary in November 2009.
In vitro, incubation of P. aeruginosa in media contain-
ing ertapenem can select for resistance; however, this 
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occurred at concentrations higher than what is typically 
seen free in the serum of patients (Livermore et al. 2005). 
Several studies evaluating if previous exposure to ertap-
enem leads to the development of resistance to group 2 
carbapenems in P. aeruginosa did not find an association 
(Lima et  al. 2009; Carmeli et  al. 2011; Eagye and Nico-
lau 2011); however, these studies did show an increased 
incidence of group 2 carbapenem resistance with previ-
ous exposure to group 2 carbapenems, aminoglycosides 
and penicillins. Most of these studies evaluate antibiotic 
usage (DOT and DDD) as the correlate to patient expo-
sure to these antibiotics rather than at the individual 
level. Via a retrospective chart review, we sought to eval-
uate the contribution, if any, of prior carbapenem use in 
individual patients that developed P. aeruginosa infec-
tions in blood or sterile sites.
Methods
Chart review
This study was approved by our local institutional review 
board. A retrospective chart review of patients hospi-
talized at UCH with a documented P. aeruginosa blood 
stream infection or P. aeruginosa from another sterile site 
(cerebral spinal fluid, pleural fluid, peritoneal fluid, bone, 
or surgically obtained tissue) identified between 2010 
and 2011 was undertaken. The point of reference for the 
data abstraction is the identification of the hospital stay 
associated with the P. aeruginosa infection from Janu-
ary 1, 2010 through December 31, 2011. P. aeruginosa 
susceptibility versus resistance was based on the on the 
susceptiblity reported at the time the clinical isolate was 
obtained. If unavailable at initial review, susceptibility 
or resistance was then classified based on disk diffusion 
testing. Antibiotic utilization data were obtained from 
the UCH pharmacy records. Classification of infections 
were defined as community-acquired, healthcare associ-
ated, or hospital acquired based on standard infection 
control surveillance definitions.
Bacterial isolates
A total of forty-four clinical isolates of P. aeruginosa 
recovered from bloodstream infections in 2010–2011 
were available for microbiological analysis. Only non-
duplicate isolates per patient were included. P. aeruginosa 
ATCC strain 27,853 was used for quality control. All clin-
ical isolates had been stored at −80 °C prior to use.
Antimicrobial susceptibility tests
Frozen P. aeruginosa isolates were serially passaged two 
times on blood agar prior to performing susceptibility 
studies. Disk diffusion (DD) testing was performed as 
recommended by the Clinical and Laboratory Standards 
Institute (CLSI) (2009). The results were interpreted 
according to CLSI parameters (CLSI 2013).
Minimal inhibitory concentrations to imipenem, mero-
penem and doripenem were additionally determined for 
each of the P. aeruginosa isolates by the E-test method 
according to the manufacturer’s instructions (AB bio-
Mérieux, Marcy l’Étoile, France). MIC values were deter-
mined manually and were interpreted according to 2013 
CLSI parameters.
Data management and statistical analysis
Study data was collected and managed using REDCap™. 
Risks for sensitive versus carbapenem resistance phe-
notypes were examined using descriptive statistics. The 
Mann–Whitney U test was used to compare risk factors 
amongst the two groups. The Fisher Exact test was used 
to test for association the disease-exposure association 
for each factor. The odds ratio and 95 % confidence inter-
val were calculated.
Variables that were statistically different between car-
bapenem resistant and carbapenem sensitive groups were 
manually entered into a logistic regression model. Vari-
ables with a p value <0.05 were retained in the final mul-
tivariable model. SPSS version 22.0 (IBM Corp. Armonk, 
NY) was used for logistical regression analysis.
Findings
Eighty patient charts were reviewed with 59 patients with 
carbapenem sensitive P. aeruginosa (CSPA)—32 blood 
isolates and 27 from sterile sites, and 21 with carbap-
enem resistant P. aeruginosa (CRPA)—15 blood isolates 
and 6 from sterile sites. Seventy six percent of the CRPA 
isolates were multi-drug resistant (≥3 classes of antibi-
otic resistance). Demographics and clinical character-
istics of the patients were similar except for more solid 
organ transplant recipients in the CRPA group (21 vs 7 %, 
p = 0.04) than in the CSPA group (Table 1). The majority 
of the infections were either hospital acquired or health-
care associated with more hospital acquired infections in 
the CRPA group (71 vs 44 %, p = 0.04) (Table 1). How-
ever, the CSPA group were more likely to have infection 
healthcare associated infection with hospitalization of at 
least 30  days prior to current hospital admission (32 vs 
10 %, p = 0.045). Patients with CRPA were more likely to 
have a Foley catheter in place at the time of infection (71 
vs 37 %, p = 0.01) but there was no difference for other 
invasive devices including central venous catheter, uri-
nary conduit, nephrostomy tubes, or nasogastric tubes. 
Fifty-eight (73  %) of the patients received at least one 
dose of antibiotics (19 received a carbapenem) prior to 
developing their Pseudomonas infection. There was more 
carbapenem use in the CRPA group prior to the onset of 
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infection (59 vs 22 %, OR 5.1, 95 % CI 1.3–20.8, p = 0.01) 
(Table 1).
Despite overall improvement in our antibiotic sensitivi-
ties to P. aeruginosa isolates, the sensitivities for carbap-
enems has not improved proportionately compared to 
the other agents (Fig.  1a). During this time, overall car-
bapenem use was increased (Fig. 1b). However, there was 
no association between CRPA and individual exposure 
to ertapenem, meropenem, imipenem, or doripenem or 
between group 1 and 2 carbapenems up to 30 days prior 
to the development of the infection. In addition, there 
was no statistical association with prior use of other anti-
biotics except for a trend towards more fluoroquinolone 
exposure in the CRPA group (47 vs 20 %, OR 3.7, 95 % 
CI 0.92–15.1, p = 0.05). Length of stay was significantly 
longer in the CRPA group (mean 44  days) compared to 
the CSPA group (mean 23 days), p = 0.02 (Table 1). Mor-
tality between the two groups was similar and there were 
no differences between the groups for death attributable 
to Pseudomonas.
Logistic regression was done for all statistically sig-
nificant variables between groups. Variables retaining 
statistical significance for carbapenem resistant infec-
tions were presence of a Foley catheter, transfer from 
another unit, prior carbapenem use, prior ertapenem 
use, prior fluoroquinolone use, and prior ciprofloxacin 
use (Table  2). To avoid redundancy between prior car-
bapenem and prior ertapenem use, only one variable was 
entered into the multivariate analysis at a time. The same 
technique was used for prior fluoroquinolone and prior 
ciprofloxacin use. Due to multiple iterations of the mul-
tivariate analysis, the odds ratios, 95 % confidence inter-
vals, and p values closest to significance are reported in 
Table  2 as Adjusted. None of the variables maintained 
significance in the multivariate analysis.
Stored isolates were available for 44 patients with blood 
stream infections. Based on documentation in the clini-
cal chart, 28 isolates were reported as sensitive to dorip-
enem, 5 were intermediate, and 6 isolates were reported 
as resistant. Five isolates did not have sensitivities 
reported in the clinical chart at the time they were origi-
nally obtained. Subsequent testing via E-test revealed a 
good correlation with the initial DD results; however, 7 
individual isolates (23 %) were reported as susceptible to 
doripenem (2), meropenem (1) or imipenem (4) based on 
DD but were considered intermediate susceptible based 
on their respective MICs. Susceptibility to one carbap-
enem did not always predict susceptibility to one of the 
other carbapenems. Based on MICs, 11 (37  %) doripe-
nem susceptible isolates were intermediate or resistant to 
meropenem and imipenem and conversely, 6 (20 %) imi-
penem intermediate or resistant isolates were found to be 
susceptible to meropenem and doripenem.
Discussion
Studies evaluating the influence of group 1 versus group 2 
carbapenems on P. aeruginosa susceptibilities (Lima et al. 
2009; Carmeli et  al. 2011; Eagye and Nicolau 2011) pri-
marily utilized antibiotic prescription data to determine 
associations between usage and subsequent resistance. In 
Table 1 Epidemiologic and  clinical characteristics of  80 










 Median (range) 55 (22–88) 57 (26–77) 0.86
Gender
 Male (%) 66 52 0.30
Race
 Caucasian (%) 81 86 0.75




 Hispanic (%) 12 10 1.00
Type of acquisition
 Hospital acquired 
(%)
44 71 0.04







 Chronic renal insuf-
ficiency (%)
19 24 0.75
 Coronary artery 
disease (%)
15 24 0.52






 Neutropenia (%) 14 14 1.00
 Solid tumor (%) 20 19 1.00




 Central venous 
catheter (%)
54 76 0.12
 Foley catheter (%) 37 71 0.01
Antibiotic use
 Prior antibiotics (%) 69 80 0.80




 Mean days (range) 23 (1–127) 44 (4–223) 0.02
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this study, while antibiotic usage was evaluated, patient 
level risk factors were assessed to determine any asso-
ciations with the susceptibility patterns of the P. aerugi-
nosa. In our study, patients with CRPA were more likely 
to have a hospital acquired infection and to have a mul-
tidrug resistant profile. Other identifiable risks included 
a Foley catheter in place at the time of infection, trans-
fer from another unit, exposure to a carbapenem prior 
to infection including a trend towards an association 
with ertapenem usage, and prior fluorquinolone use (in 
the unadjusted model). This is noteworthy in that prior 
exposure to ertapenem has not been associated with sub-
sequent carbapenem resistance; however, in the adjusted 
linear regression model, these risk factors were not statis-
tically significant.
In a case control study by Lautenbach et  al. (2006), 
patients with imipenem resistant P. aeruginosa were 
compared to those with imipenem sensitive isolates 
Fig. 1 a Antibiogram for P. aeruginosa isolates at UCH from 2002 to 2011. Arrow denotes implementation of house-wide restriction of fluoroqui-
nolones. P/T piperacillin/tazobactam, GNT gentamicin, IMI imipenem, MER meropenem, DORI doripenem, CTX ceftazidime, CIP ciprofloxacin. b 
Antibiotic usage at UCH from 2004 to 2011. There was a significant decrease of fluoroquinolones after restriction in 2004
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from all clinical sites including respiratory tract, urinary 
tract, skin or soft tissue, blood, abdomen, catheter, and 
other sites. The authors found that the only independent 
risk factor for imipenem resistance was prior FQ use. In 
addition, imipenem resistance was associate with longer 
length of hospital stay and increased mortality. We found 
a similar association with FQ use, but did not see the 
association with increased mortality; however, this may 
be a factor of a much smaller sample size in our study 
compared to the aforementioned study.
Fortaleza et  al. (2006) evaluated risk factors associ-
ated with imipenem resistant P. aeruginosa in patients 
hospitalized in Brazil. One hundred and eight patients 
were evaluated and statistically significant risk factors for 
acquisition of imipenem resistant P. aeruginosa were pre-
vious admission to another hospital, hemodialysis, and 
therapy with imipenem, amikacin, and/or vancomycin. 
Our study did not find similar associations, though again, 
our sample size was likely underpowered to detect these 
differences.
In evaluation of outcomes, length of stay was longer in 
the CRPA group. There were 5 deaths in the CRPA group 
with 3 deaths (60 %) attributed to the Pseudomonas infec-
tion and 16 total deaths in the CSPA with 9 of the deaths 
(56 %) attributed to Pseudomonas infection. Four patients 
in the CRPA group received empiric therapy with a car-
bapenem and 2 of those patients died due to on-going 
sepsis; however, there was no difference in 30-day mor-
tality between the two groups.
MIC testing of isolates revealed discordant results 
when compared to DD testing in a small percentage of 
cases and susceptibility to one carbapenem did not nec-
essarily correlate with susceptibility or resistance to the 
other carbapenems tested. Limits of the study include 
retrospective nature and small sample size.
In conclusion, patients should be evaluated for risk 
factors for the development of resistant Pseudomonas 
including use of devices, recent hospitalization, transfer 
between hospital units and prior antibiotic use includ-
ing the use of FQs and carbapenems. Prompt removal 
of devices and an aggressive antibiotic stewardship pro-
grams may help prevent the development and complica-
tions associated with CRPA.
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